Background {#Sec1}
==========

IgG4-related disease (IgG4-RD) is a relatively recently recognized chronic multi-organ autoimmune disease of unknown origin with a tendency to develop lesions at multiple sites throughout the body \[[@CR1]\]. It is known to affect various organs including the bile duct, pancreas, gallbladder, liver, lungs and salivary glands. It is characterized by elevated IgG4 levels in the serum and the affected tissues, lymphoproliferative infiltration and sclerotic fibrosis \[[@CR2], [@CR3]\]. Other typical features are occlusive phlebitis and rising IgG4-plasma cells levels \[[@CR4], [@CR5]\]. Clinically, it mimics malignancy in some patients, especially those with liver and pancreatic lesions and is often thought to necessitate surgical resection, sometimes leading to over-treatment \[[@CR6], [@CR7]\]. To date, only a few isolated cases of digestive IgG4-RD have been reported.

Case presentation {#Sec2}
=================

A 52-year-old male from southwest China presented with obstructive jaundice for 3 years, melena for 5 months and hematemesis for 10 days. The patient had been diagnosed with type 2 diabetes mellitus for 4 years, which was treated with metformin. The patient was a chronic tobacco (10 cigarettes per day) and alcohol consumer over the previous 20 years but had quit smoking and drinking for the past 3 years. Three years prior to admission to our hospital, he developed obstructive jaundice, which was investigated with abdominal computed tomography (CT) and revealed multiple hypodense lesions in the liver and pancreatic head mass. He underwent cholecystectomy, choledochojejunostomy and biopsies from the liver and pancreatic lesions. Histopathology revealed chronic cholecystitis with lymphocytic, plasmacytic and eosinophilic infiltration of the gallbladder, liver and pancreatic parenchyma.

The physical examination was unremarkable (height − 165 cm, weight -- 50 kg). Laboratory tests revealed hemoglobin levels of 75 g/L, a platelet count of 80 × 10^9^/L, 30.0 g/L albumin levels, and serum potassium levels of 3.20 mmol/L (Table [1](#Tab1){ref-type="table"}). The fecal occult blood was positive.Table 1Comparison of IgG4 parameters and routine blood and markers for liver function before and after treatmentParameterAdmission dayConfirmed dayAfter treatment 8 daysFollow up 1 monthFollow up 3 monthsFollow up 6 monthsFollow up 9 monthsIgG4 (g/L)--29.2018.409.864.741.871.70IgG (g/L)--24.519.4----8.80--CRP (mg/ L)5.46------2.621.32--TBIL (μmol/L)12.111.756.423.414.17.7--DBIL (umol/L)6.55.444.516.46.13.1--ALT (IU/L)41133151344429--AST (IU/L)4024167572826--ALB (g/L)3036.434.837.135.242.1--PLT(\*10^9^/L)80958810681110140HGB (g/L)75619871122114123*IgG4* Immunoglobulin G4 subtype, *IgG* Immunoglobulin G, *CRP* C-reactive protein, *TBIL* total bilirubin, *DBIL* direct bilirubin, *ALT* alanine aminotransferase, *AST* aspartate aminotransferase, *ALB* albumin, *PLT* platelet, *HGB* hemoglobin

On the day of admission, the patient developed repeated painless hematemesis of about 2100 mL, which was associated with hypotension and tachycardia. He was resuscitated with intravenous, blood and norepinephrine infusions. Laboratory tests revealed hemoglobin levels of 47.5 g/L, platelet count levels of 38 × 10^9^ L and serum albumin 25.8 g /L. The day after admission, the patient again developed hematemesis of about 500 mL, for which he was treated with somatostatin, terlipressin and pantoprazole infusion. Sengstaken-Blakemore tube were placed to hemostasis by compression and tube feeding hemostatic medicine. After 4 days of medical intervention, the patient's gastrointestinal bleeding gradually stopped. Esophagogastroduodenoscopy revealed a duodenal ulcer (A1 stage) with active bleeding, gastric mucosal erosions and esophageal varices (mild). Contrast enhanced computed tomography of the abdomen with three-dimensional reconstruction exposed multiple nodular dense shadows with dilatation of the main pancreatic duct in the tail region (Fig. [1d](#Fig1){ref-type="fig"}). Images of the liver showed numerous hypodense nodules with mild contrast enhancement, ascites and intrahepatic bile duct dilatation (Fig. [1a](#Fig1){ref-type="fig"}). Additionally, there were multiple enlarged lymph nodes in the hepatoduodenal ligament around the abdominal aorta (Fig. [1b](#Fig1){ref-type="fig"}) and mesenteric lymph nodes with bilateral pleural effusion (Fig. [1c](#Fig1){ref-type="fig"}). In view of the liver disease with portal hypertension and esophagogastric varices, a transjugular intrahepatic portosystemic shunt (TIPS) procedure was performed under local anesthesia and regional portal hypertension, splenic vein and portal vein obstruction were detected. Subsequently, the patient re-bleed both 14 days and 20 days after admission, about 600 mL and 400 mL, respectively. The patient was treated with somatostatin, pantoprazole infusion and blood transfusion. Gastroscopy identified an ulcer (1.5 cm × 1.2 cm) in the anterior wall of the duodenal bulb that was not actively bleeding (Fig. [2a](#Fig2){ref-type="fig"}, Fig. [2b](#Fig2){ref-type="fig"}). Pathological examination of the ulcer biopsy verified a moderate degree of chronic mucosal inflammation.Fig. 1Abdominal computed tomography. Images of the liver showed numerous hypodense nodules with mild contrast enhancement, ascites and intrahepatic bile duct dilatation (**a**). There were multiple enlarged lymph nodes in the hepatoduodenal ligament around the abdominal aorta (**b**). Mesenteric lymph nodes with bilateral pleural effusion (**c**). Multiple nodular dense shadows with dilatation of the main pancreatic duct in the tail region (**d**)Fig. 2Gastroscopy findings. An ulcer (1.5 cm × 1.2 cm) in the anterior wall of the duodenal bulb and a lot of white mosses in the fundus of stomach (**a**, **b**)

When investigating the recurrent bleeds, serum IgG4(0.035--1.500 g/L)and IgG(8\~ 15.5 g/L)were found to be 29.200 g/L and 24.50 g/ L respectively and IgG4 disease was suspected (Table [1](#Tab1){ref-type="table"}). The patient's prior surgical pathology specimens were retrieved for IgG4 immunohistochemical examination. Immunohistochemical staining revealed increased IgG-positive and IgG4-positive plasma cells in the liver lesions (IgG4 positive cells 30--60/ high power field (HPF); Fig. [3b](#Fig3){ref-type="fig"}), pancreas (IgG4 positive cells 30--80/HPF; Fig. [3d](#Fig3){ref-type="fig"}) and gallbladder (IgG4 positive cells 30--80/HPF; Fig. [3f](#Fig3){ref-type="fig"}). Staining of the duodenum ulcer biopsy also showed more than 100 IgG4-positive cells per HPF (Fig. [3h](#Fig3){ref-type="fig"}). Based on these findings, a definitive diagnosis of IgG4-RD was made.Fig. 3Pathologic findings. **a** Diaminobenzidine staining of liver specimens revealed focal necrosis of the liver surrounded by fibrous tissue. The focal necrosis area revealed infiltration by lymphocytes, plasma cells and eosinophils. Peripheral hepatocytes were partially silt. **b** Immunoglobulin G (IgG) immunohistochemical staining showing increased numbers of IgG-positive plasma cells in the liver lesions (30--60/ high power field \[HPF\], × 400). **c** Diaminobenzidine staining of pancreas tissues revealed focal areas of glandular atrophy accompanied by lymphocyte, plasma cell and eosinophil infiltration and fibrous tissue hyperplasia. **d** IgG immunohistochemical staining showing increased numbers of IgG-positive plasma cells in the pancreas (30--80/HPF, × 400). **e** Diaminobenzidine staining of gallbladder tissue revealed chronic cholecystitis, focal lymphoid hyperplasia, formation of lymph follicles and infiltration of the gallbladder wall by the lymphocytes, plasma cells and eosinophils. **f** IgG immunohistochemical staining showing increased numbers of IgG-positive plasma cells in the gallbladder (30--80/HPF, × 400). **g** Hematin and yepin staining of duodenum tissue revealed lymphocytic, plasmacytic and neutrophilic infiltration of the inner layer of the duodenal mucosa with congestion and dilatation of the blood vessels. **h** IgG immunohistochemical staining showing increased numbers of IgG-positive plasma cells in the duodenum (\> 100 /HPF, × 400)

The patient was administered 40 mg/d prednisone intravenously for 7 days without any side effects followed by oral prednisolone 40 mg/d for 1 week. Laboratory tests indicated a reduction in the serum IgG4 levels 8 days after initiating prednisone but the liver function continued to be impaired (Table [1](#Tab1){ref-type="table"}). As the patient improved symptomatically, he was discharged on a regime of prednisolone and mycophenolate mofetil.

Since discharge until the time of writing, during the 11 monthly visits since starting steroid therapy, laboratory tests indicate significant improvements in the patient's serum IgG4 subtype, liver function and hemogram tests (Table [1](#Tab1){ref-type="table"}).

Discussion and conclusions {#Sec3}
==========================

IgG4-RD was first described in patients with sclerosing cholangitis, known as autoimmune pancreatitis (AIP) type I. Subsequently, IgG4-RD was found to affect other organs \[[@CR6]\]. At present IgG4-RD is believed to be a systemic disease and diagnostic criteria for IgG4-RD \[[@CR8], [@CR9]\] include: (1) single or multiple organs with diffuse or localized swelling, masses, nodules and/or hypertrophic lesions; (2) elevated serum IgG4 levels (≥135 mg/dL); and (3) histopathologic features that include marked lymphocytic and plasma cell infiltration and fibrosis, with IgG4-positive plasma cell infiltration (IgG4/IgG positive cell ratio of 40% and IgG4-positive plasma cells exceeding 10/HPF). Diagnosis of IgG4-related is confirmed when all of the following are fulfilled: (1), (2) and (3). Diagnosis is likely if criteria (1) + (3) are fulfilled, possible if (1) + (2) are fulfilled and unlikely if only (1) presents.

Notably, the biliary tract and pancreas are the organs most frequently affected by IgG4-RD \[[@CR10]\]. Few studies have reported isolated cases of IgG4-RD in other digestive organs, such as in the esophagus, stomach, liver or duodenum \[[@CR7]\].

A recent review of IgG4-RD cases reporting on gastrointestinal lesions showed that most patients present with multiple organ disease involvement, including the stomach, duodenum, liver, bile duct, esophagus, jejunum, lymph nodes and pancreas (Table [2](#Tab2){ref-type="table"}). Six patients presented with obstructive jaundice as the main clinical manifestation \[[@CR11]--[@CR16]\] and others presented with varied clinical symptoms \[[@CR17]--[@CR28]\]. Gastrointestinal bleeding was not reported in any of the studies. Our patient had recurrent gastrointestinal bleeding due to a duodenal ulcer. The ulcer failed to heal with standard treatment. Serum IgG4 was elevated in most of the cases reviewed, similar to our case, though was normal in three reports \[[@CR11], [@CR13], [@CR17]\] and was not reported in two cases \[[@CR11], [@CR18]\]. The diagnosis of IgG4-RD was based on a combination of features that include clinical parameters, serology, immunohistochemistry, imaging and histopathology. In the present case, the diagnosis of IgG4-RD was initially missed in the histological analysis of the liver and pancreatic biopsy and gallbladder samples. When IgG4-RD was suspected based on the clinical and laboratory findings, IgG4 immunostaining was undertaken and the IgG4-RD diagnosis was confirmed. In our literature review, there were eight patients treated through surgery, 10 patients by corticosteroids, two were given corticosteroids after surgery, and in two patient studies, the treatment course was not reported (Table [2](#Tab2){ref-type="table"}). Our patient responded partially to steroid therapy and required other immunosuppressive agents for a complete and successful response.Table 2Summary of demographic, radiographic and clinical information from a review of 18 previously published cases of IgG4-Related gastrointestinal disordersStudyAge, GenderClinical SymptomsLaboratoryCNS Imaging (modality)Biopsy SourceOrgan InvolvementTreatment, ResponseFong et al., 2013 \[[@CR11]\]42, MObstructive jaundice, pruritus, pale stools, weight loss, tea-colored urineIncreased liver enzymes, IgG4 normalExtrahepatic duct presented with a mural thickening (CT), stricture in the middle of bile duct with proximal biliary dilatation (ERCP)Duodenal ampullaDuodenal, liverMarked79, MObstructive jaundice, weight lossNot reportedMild dilatation of the biliary tree (CT)Not reportedPancreas, biliarySurgeryRungsakulkij et al., 2017 \[[@CR12]\]56, MObstructive jaundiceIncreased serum IgG4Bile duct obstruction(CT); stricture of hepatic duct (ERCP)AmpullaryBile ductSurgeryCai et al., 2014 \[[@CR13]\]57, MJaundice, upper abdominal DiscomfortIgG4 serum normalMass observed in the hepatic duct (CT), hepatic duct and proximal bile duct dilatation (MRI)Bile ductBile ductSurgeryEl Euch et al., 2017 \[[@CR14]\]70, MObstructive jaundice, anorexia, abdominal pain, \\weight lossIncreased liver enzymes, and Serum IgG4Diffuse pancreatic swelling and strictures of the main pancreatic duct (CT), thickened rim surrounding the pancreatic duct (MRI)Not reportedPancreaticMarkedMiki et al., 2015 \[[@CR15]\]69, MJaundice, steatorrheaIncreased liver enzyme, and serum IgG4Thickening of the bile duct wall, compressing the right portal vein (CT); bile duct lesions involving the left and right hepatic ducts (ERCP)Bile ductBile ductSurgerySivakumaran et al.., 2014 \[[@CR16]\]51, FJaundice, weight lossIncreased carbohydrate antigen 19--9Intrahepatic duct dilatation and a hilar stricture (CT), a mass at the portal hepatitis (MRI)LiverliverSurgery, MarkedRodriguez et al., 2016 \[[@CR17]\]55, FAbdominal pain, weight lossIgG4 and other blood indices were normalA mass in the pancreas(CT), hypermetabolic of the pancreas tail, bone marrow, and spleen, diffuse lymphadenopathy (PET)Bone marrowPancreasMarkedKondo et al., 2016 \[[@CR18]\]78, MBilateral leg edemaNot reportedSclerosing cholangitis (MRI)PleuralPleura, bile duct, pericardiumMarkedYang et al., 2015 \[[@CR19]\]60, MAcid refluxIncreased serum IgG4Multiple masses in the esophagus stomach, and liver (CT)Esophagus, stomachEsophagus, stomach and liverMarkedMiyajima et al., 2017 \[[@CR20]\]50, MRight upper pain, anorexiaLeucocytosisTwo liver masses (CT)LiverLiverSurgeryLi et al., 2016 \[[@CR21]\]57, FPruritusIncreased liver enzymes and serum IgG4Dilation of intrahepatic bile duct and lesions occupying the on head of pancreas, anastomotic stenosis (MRCP)BiliaryBiliarySurgeryChen et al., 2016 \[[@CR22]\]58, MPruritusIncreased total bilirubin, direct bilirubin, lipase, and serum IgG4Stricture of the distal bile duct and dilatation of the pancreatic duct (MRI); pancreatic duct with double duct sign (ERCP)Not reportedPancreasMarkedShimamura et al., 2015 \[[@CR23]\]74, MNot reportedIncreased serum IgG4Low-density lesions, rim-like lesions in the bilateral kidneys (CT)Gastric mass and KidneyStomach and kidneyMarkedBulanov et al., 2016 \[[@CR24]\]62, FSevere weakness and fatigueHemoglobin reduction, increased serum IgG4Chronic ulcerative lesion, thickening of the stomach wall(CT)Gastric mass and regional lymph nodesStomach, lymph nodesSurgeryTakasumi et al., 2016 \[[@CR25]\]63, FNot reportedthrombocytopenia, increased serum IgG4 and IgMEnlargement of the submandibular glands, diffuse enlargement of the pancreas (CT)Bone marrow, liverLiverMarkedKim et al., 2016 \[[@CR26]\]61, MWeakness, easy fatigability, weight lossIncreased liver enzymes and serum IgG4Type IV hilar cholangiocarcinoma with periductal invasion into underlying hepatic parenchyma (MRI), multiple enlarged lymph nodes in left axillary (PET)Intrahepatic bile ductMarkedMatsunaga et al., 2014 \[[@CR27]\]72, MNot reportedIncreased hepatobiliary enzymes, serum IgG, and tumor markersEnhancement in the pancreatic head, stenosis in the bile duct head and dilatation (CT), diffuse pancreatic ductal stenosis (MRI)Duodenal papillaDuodenumNot reportedVan et al., 2017 \[[@CR28]\]26, MLymphadenopathy, splenomegalyIncreased IgG4, reduced T lymphocyteNot reportedPancreasPancreasNot reported*CT* computed tomography, *ERCP* endoscopic retrograde cholangiography, *MRI* magnetic resonance imaging, *PET* positron emission tomography

IgG4-RD can affect multiple gastrointestinal organs simultaneously or over different time periods. The clinical manifestations can mimic malignancy or other benign diseases such as portal hypertension, acid peptic disease. A high index of suspicion is required to make an accurate diagnosis and avoid unnecessary surgical interventions.
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